| Interconnected microphysiological systems for quantitative biology and pharmacology studies CD Edington, WLK Chen, E Geishecker, T Kassis, LR Soenksen, ... Scientific reports 8 (1), 4530, 2018 | 401 | 2018 |
| Combining the ‘bottom up’and ‘top down’approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data N Tsamandouras, A Rostami‐Hodjegan, L Aarons British journal of clinical pharmacology 79 (1), 48-55, 2015 | 261 | 2015 |
| Integrated Gut and Liver Microphysiological Systems for Quantitative In Vitro Pharmacokinetic Studies N Tsamandouras, WLK Chen, CD Edington, CL Stokes, LG Griffith, M Cirit The AAPS journal 19, 1499-1512, 2017 | 183 | 2017 |
| Quantitative assessment of population variability in hepatic drug metabolism using a perfused 3D human liver microphysiological system N Tsamandouras, T Kostrzewski, CL Stokes, LG Griffith, DJ Hughes, ... Journal of Pharmacology and Experimental Therapeutics 360 (1), 95-105, 2017 | 99* | 2017 |
| Capsaicin-evoked cough responses in asthmatic patients: evidence for airway neuronal dysfunction I Satia, N Tsamandouras, K Holt, H Badri, M Woodhead, K Ogungbenro, ... Journal of Allergy and Clinical Immunology 139 (3), 771-779. e10, 2017 | 92 | 2017 |
| Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population‐modeling approach N Tsamandouras, G Dickinson, Y Guo, S Hall, A Rostami‐Hodjegan, ... Clinical Pharmacology & Therapeutics 96 (1), 90-100, 2014 | 71 | 2014 |
| Development and application of a mechanistic pharmacokinetic model for simvastatin and its active metabolite simvastatin acid using an integrated population PBPK approach N Tsamandouras, G Dickinson, Y Guo, S Hall, A Rostami-Hodjegan, ... Pharmaceutical research 32, 1864-1883, 2015 | 64 | 2015 |
| Reduced Physiologically-Based Pharmacokinetic Model of Repaglinide: Impact of OATP1B1 and CYP2C8 Genotype and Source of In Vitro Data on the Prediction … M Gertz, N Tsamandouras, C Säll, JB Houston, A Galetin Pharmaceutical research 31, 2367-2382, 2014 | 55 | 2014 |
| Efficacy and safety of oral small molecule glucagon-like peptide 1 receptor agonist danuglipron for glycemic control among patients with type 2 diabetes: a randomized clinical … AR Saxena, JP Frias, LS Brown, DN Gorman, S Vasas, N Tsamandouras, ... JAMA Network Open 6 (5), e2314493-e2314493, 2023 | 32 | 2023 |
| Modelling of atorvastatin pharmacokinetics and the identification of the effect of a BCRP polymorphism in the Japanese population N Tsamandouras, Y Guo, T Wendling, S Hall, A Galetin, L Aarons Pharmacogenetics and Genomics 27 (1), 27-38, 2017 | 20 | 2017 |
| Reduction of a Whole-Body Physiologically Based Pharmacokinetic Model to Stabilise the Bayesian Analysis of Clinical Data T Wendling, N Tsamandouras, S Dumitras, E Pigeolet, K Ogungbenro, ... The AAPS Journal, 1-14, 2015 | 19 | 2015 |
| Incorporation of stochastic variability in mechanistic population pharmacokinetic models: handling the physiological constraints using normal transformations N Tsamandouras, T Wendling, A Rostami-Hodjegan, A Galetin, L Aarons Journal of pharmacokinetics and pharmacodynamics 42 (4), 349-373, 2015 | 15 | 2015 |
| Physiologically relevant, humanized intestinal systems to study metabolism and transport of small molecule therapeutics A Sawant-Basak, AD Rodrigues, M Lech, R Doyonnas, M Kasaian, ... Drug Metabolism and Disposition 46 (11), 1581-1587, 2018 | 14 | 2018 |
| Tolerability, safety and pharmacodynamics of oral, small‐molecule glucagon‐like peptide‐1 receptor agonist danuglipron for type 2 diabetes: a 12‐week, randomized, placebo … AR Saxena, JP Frias, DN Gorman, RN Lopez, N Andrawis, ... Diabetes, Obesity and Metabolism 25 (10), 2805-2814, 2023 | 9 | 2023 |
| Impact of Phase 1 study design on estimation of QT interval prolongation risk using exposure–response analysis N Tsamandouras, S Duvvuri, S Riley Journal of Pharmacokinetics and Pharmacodynamics 46 (6), 605-616, 2019 | 3 | 2019 |
| Once-daily oral small molecule GLP-1R agonist PF-07081532 robustly reduces glucose and body weight within 4-6 weeks in adults with type 2 diabetes and non-diabetic adults with … C Buckeridge, N Tsamandouras, S Carvajal-Gonzalez, LS Brown, ... Diabetologia 65 (SUPPL 1), S60-S60, 2022 | 2 | 2022 |
| Development and applications of physiologically-based pharmacokinetic models for population data analyses N Tsamandouras PQDT-UK & Ireland, 2015 | 2 | 2015 |
| Oral small molecule GLP-1 receptor agonist danuglipron (PF-06882961) results in glucose lowering and body weight loss over 16 weeks in adults with type 2 diabetes AR Saxena, J Frias, LS Brown, DN Gorman, N Tsamandouras, ... DIABETOLOGIA 65 (SUPPL 1), S302-S302, 2022 | 1 | 2022 |
| Employing zero-inflated beta distribution in an exposure-response analysis of TYK2/JAK1 inhibitor brepocitinib in patients with plaque psoriasis N Tsamandouras, R Qiu, JH Hughes, K Sweeney, JP Prybylski, ... Journal of Pharmacokinetics and Pharmacodynamics, 1-13, 2024 | | 2024 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF‐06817024 in Healthy Participants, Participants with Chronic Rhinosinusitis with Nasal Polyps, and … SI Danto, N Tsamandouras, P Reddy, S Gilbert, J Mancuso, K Page, ... The Journal of Clinical Pharmacology, 2023 | | 2023 |
